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Purpose: Cohesive Polydensified Matrix® hyaluronic acid (CPM-HA) volumizer has been 
used successfully for several years to reverse biometric volume loss during facial aging. This 
observational study explored the additive effect on nasolabial folds when CPM-HA volumizer 
is injected into the neighboring cheek area.
Patients and methods: In this open-label, prospective, postmarketing noninterventional study, 
18 adult patients seeking esthetic enhancement of the lateral cheek hollows and cheekbone area 
were injected with CPM-HA volumizer integrated with lidocaine (CPM-HA-VL) in the upper 
or lower cheek area. Safety and performance of CPM-HA-VL up to 12 months after injection 
with follow-up visits at week 4 and month 3, 6, and 12 were assessed. The primary endpoint was 
improvement of cheek fullness on the validated Merz Aesthetics Scales. Additionally, changes 
in nasolabial folds were quantified using a phaseshift rapid in vivo measurement of skin optical 
three-dimensional (3D) in vivo measurement device. 
Results: Patients (94.4% female, median age 52 years, age range 39–69 years) were injected 
with a mean volume of 2.5±1.1 mL CPM-HA-VL per side. Immediately after injection, mean 
severity for upper and lower cheek fullness assessed on the validated MAS improved from 2.5±0.6 
and 2.8±0.5, respectively, to 1.0±0.0, and remained unchanged through month 12. Improvement 
in relation to baseline was attested on the Global Aesthetics Improvement Scale for all assess-
ments. Compared with baseline, the following assessments offered a statistical significance in 
the reduction of wrinkle depth of nasolabial folds (maximum depth reduction by 30.4% at 3 
months) according to optical 3D in vivo measurements. Pain during injection was minimal and 
abated within 30 minutes. Treatment was well tolerated and led to great patient satisfaction.
Conclusion: CPM-HA-VL injected into the upper and lower cheeks led to long-lasting satis-
factory cosmetic results in cheek augmentation as well as in reducing depth of nasolabial folds 
adjacent to the injection site. 
Keywords: CPM-HA-VL volumizing filler, facial rejuvenation, esthetic procedure, dermal 
filler, PRIMOS 3D
Introduction
Alterations in the craniofacial skeleton are a common accompanying effect of the 
aging process. Changes in the relative dynamics of bone expansion and bone resorp-
tion lead to a significant loss of facial bone with age.1 In consequence of the resulting 
biometric volume loss, the jaw line becomes less pronounced, the skin in cheeks, under 
the eyes, and around the nose and mouth yields to gravity and starts sagging. This 
process is further promoted by the decrease in muscle tone and increasing laxity of 
ligaments. In addition, wrinkle formation intensifies with the deceleration of collagen 
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and elastin production.2 Prompted by the wish to maintain 
a youthful appearance, increasingly more individuals seek 
esthetic correction of this facial aging process by minimally 
invasive procedures. 
In previous decades, facial rejuvenation focused on 
the treatment of wrinkles alone. However, with growing 
understanding of the facial aging process in recent years, the 
primary focus has shifted to the reversion of volume loss. 
Enhancement of the lateral cheek hollows and cheekbone 
area recreates midface volume, smoothens nasolabial folds, 
and restores the youthful V-form of the face.3 Therefore, the 
current treatment strategies aim at restoring juvenile propor-
tions of the entire face by injection of a soft-tissue filler. 
Volume fillers based on hyaluronic acid (HA) have 
become increasingly popular because of their good per-
formance and favorable safety profile.4 Depending on the 
individual treatment goal and area of application, available 
HA fillers vary in their clinical characteristics which are 
determined by particle size, the type of cross-linking agent 
used, the degree of cross-linking, the percentage of cross-
linked HA, the amount of free unlinked HA, and the elastic 
modulus (G′).5 For the enhancement of the lateral cheek hol-
lows and cheekbone area, the use of Cohesive Polydensified 
Matrix® (CPM)-HA volumizer is supported by 5 years of 
clinical experience. Resulting from CPM technology, it is 
characterized by variable cross-linking densities within the 
gel – denser areas for the volumizing effect and areas of lesser 
density for cohesivity of the matrix. This property allows 
for better integration into soft tissues and prevention of the 
Tyndall effect.6 Furthermore, the CPM-HA-specific plasticity 
of this filler allows the practitioner to mold and sculpt the 
product easily into the desired shape after the injection in 
order to achieve optimal esthetic results. Clinical data have 
confirmed the safety and efficacy of the CPM-HA volumizer 
with regard to the respective areas that have been injected.7–10
While concomitant correction of the nasolabial fold has 
been observed by volumizing the cheek and the lost malar fat 
pads,10 there is little information on the extent and duration of 
the additive effect a dermal filler has on the areas adjacent to 
the injection site. Therefore, the present observational study 
further explored the effect on nasolabial folds when a filler 
is injected into the cheek.
Materials and methods
The study was designed as an open-label, prospective, non-
interventional study performed at a single center in Germany. 
It was conducted from July 2014 to November 2015 in accor-
dance with the Declaration of Helsinki and was reviewed and 
approved by the Ethics Committee of the Ludwig-Maximilian 
University. All patients provided written informed consent 
before enrollment in the study.
The primary endpoint was improvement of cheek fullness 
on the validated Merz Aesthetics Scales (MAS). Enhance-
ment of the lateral cheek hollows and cheekbone area by a 
CPM-HA volumizer with integrated lidocaine (CPM-HA-
VL, Belotero® Volume Lidocaine; Merz Pharmaceuticals 
GmbH, Frankfurt, Germany) was expected to lead to a 
reduction of the depth of nasolabial folds after injection in 
the cheek area. These changes were objectified and evaluated. 
Additional secondary endpoints included the assessment 
of safety and patient satisfaction of CPM-HA-VL up to 12 
months postinjection.
A total of 18 adult patients seeking esthetic treatment in 
the upper or lower cheek area were recruited from the inves-
tigator’s patient pool. Prior to treatment at the first visit (V1) 
baseline characteristics were documented, including a sever-
ity assessment of the area to be treated using the validated 
5-point MAS for upper and lower cheek fullness.11
Furthermore, depth of nasolabial folds was measured 
using a phaseshift rapid in vivo measurement of skin (PRI-
MOS) optical three-dimensional (3D) in vivo measurement 
device (GFMesstechnik GmbH, Teltow, Germany).12–16 To 
observe changes in fold depth, a parallel stripe pattern of 
light was projected which was afterwards captured by a 
camera system and plotted in a color-coded height map of 
the measured surface.12 At each visit, measurements were 
performed by the same investigator. 
During the first visit, patients were treated in the lower and 
upper cheek area with CPM-HA-VL according to the inves-
tigator’s usual practice and patients’ needs. The CE-marked 
dermal filler consists of 26 mg/mL HA from biofermentation 
origin cross-linked with 1,4-butanediol diglycidyl ether. The 
volumes to be injected as well as the injection techniques 
were subject to the investigator’s discretion. During and 30 
minutes after the injection, pain was assessed on an 11-point 
visual analog scale (VAS) ranging from “0” (no pain) to “10” 
(extreme pain). Immediately after the injection and at follow-
up visits 4 weeks (V2), 3 (V3), 6 (V4), and 12 months (V5) 
postinjection the following assessments were conducted: 
changes in 1) severity of cheek hollowness and 2) depth of 
nasolabial folds were documented. Performance was assessed 
using the MAS. The cosmetic result was rated in comparison 
to baseline using the Global Aesthetics Improvement Scale 
(GAIS). To verify the comparison, photographs were taken 
at each visit. Written informed consent was obtained from 
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CPM-HA-VL improves cheek fullness while reducing NFL wrinkle depth
application and publication of the fully identifiable pictures. 
Patient satisfaction was assessed on a 6-point Likert scale 
(very good, good, satisfactory, sufficient, poor, insufficient). 
Patients also stated whether they would undergo treatment 
with CPM-HA-VL again. Tolerability was assessed on a 
5-point Likert scale (very good, good, satisfactory, sufficient, 
poor). Reactions at the injection site were documented at 
each visit.
Statistical methods
The analyses were descriptive based on the observed cases. 
Continuous variables were summarized by number, mean, 
SD, median, minimum, and maximum. For quantitative 
variables, absolute and percent frequencies (N, %) were 
calculated. Evaluation of parameters measuring the clinical 
course was performed by intraindividual difference analysis 
(first vs last examination) using the Wilcoxon signed rank 
test. Difference was calculated per patient and subsequently 
averaged. Patients with missing data for one or both variables 
were not imputed. All tests were two-sided, and significance 
was declared at the 0.05 level.
Results
A total of 17 females and 1 male were enrolled between July 
and November 2014. Median age was 52 years (range 39–69). 
At baseline, mean severity on the MAS for upper and lower 
cheek fullness was 2.5±0.6 and 2.8±0.5, respectively. Mean 
depth of nasolabial folds at baseline was 3.2±1.6 mm (right) 
and 3.7±2.1 mm (left). There was no statistically significant 
difference between the left and right side. Therefore, values 
were pooled for the analysis of the clinical course. 
Mean injected volume was 2.5±1.1 mL per side of the 
face. The fanning technique using a blunt cannula 22G 
50 mm provided within the package was applied in most 
cases (72.2%), while CPM-HA-VL was administered using 
bolus and fanning technique in 3 patients (16.7%, n=2 not 
reported). No additional anesthetic or cooling was applied. 
Mean pain during and 30 minutes postinjection was rated 
1.5±1.1 (range 0–3) and 0.1±0.4 (range 0–1.5) on the VAS, 
respectively. Five patients (27.8%) felt no pain at all during 
the injection. Thirty minutes postinjection, only 2 patients 
still felt minimal pain (0.5 and 1.5 on the VAS, respectively). 
Efficacy
All patients showed significant increase of cheek volume and 
decreases in wrinkle depth at all postinjection measurements 
compared with baseline. All patients experienced lasting 
improvement on the MAS throughout the study period. Mean 
severity of the upper and lower cheek on the MAS improved 
to 1.0±0.0 after treatment and remained unchanged through 
month 12. Improvement in relation to baseline was attested 
on the GAIS for all postinjection assessments (Figure 1A). 
Results on the GAIS were consistent with the photo docu-
mentation (Figure 1B, C).
Matching of PRIMOS 3D measurements indicated that 
the effect on nasolabial folds occurred immediately after 
the injection. Wrinkle depth of nasolabial folds continued to 
decrease during the first 3 months postinjection (Figure 2). 
Months 6 (2.799±2.004 mm) and 12 (3.067±1.713 mm) 
showed slight increases in wrinkle depth compared with 
month 3 (2.769±1.849 mm), but the reduction compared 
with baseline remained significant (Figure 3).
Patient reported outcomes
The clear majority of patients (94.4%) rated their satisfac-
tion with the treatment result as very good immediately after 
the injection as well as 4 weeks and 3 months postinjection 
(Figure 4). The rating continued to be favorable (very good 
or good) during the remaining visits. One patient assessed 
satisfaction with the result as good immediately and 4 weeks 
after the injection. With one exception, all patients stated that 
they would undergo the treatment again. 
Safety
The investigator rated the tolerability of the product as good 
or very good in all patients (Figure 5). Mild transient redness 
was observed in 1 patient for a brief period immediately after 
injection. No other adverse events or reactions at the injec-
tion site were reported. In total, 13 patients completed the 
12-month follow-up visit. Five patients dropped out of the 
study (N=1 at month 3, N=2 at month 6, N=2 at month 12) 
due to the time required for the assessments.
Discussion
The study with 18 patients confirmed the good performance 
and safety of lidocaine containing CPM-HA volumizer for 
augmentation of the cheeks. Improvement was visible imme-
diately after the injection and lasted up to 12 months. Dur-
ing the entire postinjection period, patients showed a mean 
improvement of 1.5 points on the MAS when compared with 
baseline. The positive results achieved in cheek augmenta-
tion are in line with previous studies.17,18 The long-lasting 
treatment success in cheek augmentation may be attributed 
to the high capacity of CPM-HA-VL to resist vertical and 
dynamic compression which makes CPM-HA-VL ideal for 
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implantation.19 Clinical studies and postmarketing clinical 
observations have shown a lasting effect without touch-up 
up to 18 months.18,20,21 Compared to other dermal fillers, 
CPM-HA-VL has an intermediate elastic modulus (G′) of 
300 Pa19 which leads to greater tissue supporting capacity 
and consequently better volume efficiency.22 Furthermore, 
CPM-HA-VL benefits from the high compression parameters 
E′ and F
N
, which confer the ability to apply mechanical pres-
sure on fibroblasts in the extracellular matrix, thus stimulating 
the synthesis of de novo collagen.19 This recently discovered 
connection between HA injection and induction of collagen 
synthesis may contribute to explaining the clinical persistence 
of the treatment effect which outlasts the bioavailability of the 
filler product in the dermis.23 During the process of optimal 
tissue integration over the first weeks after implantation, 
CPM-HA-VL continues to develop, thus achieving a pleas-
ing 3D effect. Furthermore, the filler binds water, leading to 
an additional volumizing effect not restricted to the treated 
area, but extending to the adjacent regions as well, such as 
the nasolabial folds in this study. The good integration into 
the tissue24 also ensures that the filler material remains at the 
injection site without caudal migration.
Beyond the beneficial effects observed in cheek aug-
mentation, CPM-HA-VL injected into the upper and lower 
cheeks also had an impact on the nasolabial folds.25 This 
result was to be expected because deflation of the midface 
Figure 1 Assessment of the cosmetic result (A) on the GAIS and by means of photo documentation of (B) a 59-year-old patient and (C) a 55-year-old patient. 
Abbreviation: GAIS, Global Aesthetics Improvement Scale.
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CPM-HA-VL improves cheek fullness while reducing NFL wrinkle depth
is the primary cause of nasolabial folds.22 However, to the 
best of our knowledge, this is the first study that objectively 
quantified the extent of the effect on a location adjacent to the 
injection site. There was a significant long-term reduction in 
wrinkle depth. The added positive impact on nasolabial folds 
spares the patient the necessity to undergo further treatment 
Figure 2 PRIMOS 3D photo documentation and wrinkle depth (derived from the matching mode program of PRIMOS) over the course of the study. Green and blue colors 
indicate deeper areas.
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for this indication, thus reducing treatment costs as well as 
inconveniences and risks associated with minimally invasive 
procedures involving injectables. Accordingly, these objec-
tive results reflected in the subjective patient assessment: all 
patients were satisfied with the cosmetic result. 
Due to the lidocaine content in the filler product, addi-
tional anesthetics were not required. After 30 minutes, pain 
had abated in almost all patients. Studies have shown that 
lidocaine integrated into the filler reduced the perception of 
pain during the injection and correlated with higher patient 
satisfaction.26 Although injection site reactions such as red-
ness, swelling, and bruising are expected with any type of 
dermal filler injection,17 only 1 event of redness was reported. 
Consistently, most patients in the present study stated their 
willingness to repeat the procedure. 
This study is limited by its noninterventional design 
and lack of a control group as well as the low number of 
patients. However, by use of standardized objective assess-
ment measures, such as the PRIMOS optical 3D in vivo 
measurement, solid data were obtained. The technique has 
been repeatedly employed in the analysis of subtle wrinkles 
and other indications such as scars.14–16 Lateral solution in the 
two-digit micrometer range enables high precision imaging 
which allows the analysis of subtlest irregularities on the 
skin surface. The use of photo documentation also increased 
data quality and ruled out recall bias when comparing the 
cosmetic result with baseline. 
From investigations of the aging face, experts have come 
to the conclusion that changes occur in all tissue structures and 
that a change in one area may influence changes in neighboring 
tissues.27 This observation may also be applicable for the reverse 
process of restoring youthful proportions. Therefore, the addi-
tive effect on nasolabial folds observed in this study supports 
the paradigm shift toward considering all structural changes in 
the aging face and the interdependency between them instead 
of focusing treatment on individual lines and folds.
Conclusion
CPM-HA-VL injected into the upper and lower cheeks led 
to satisfactory cosmetic results in cheek augmentation as 
well as in reducing depth of nasolabial folds adjacent to the 
injection site. The effect lasted up to 12 months and was 
associated with minimal levels of transient injection-related 
pain, leading to a high degree of patient satisfaction.
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